These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 17313620

  • 1. Ranibizumab for the treatment of neovascular AMD.
    Kaiser PK, Do DV.
    Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620
    [Abstract] [Full Text] [Related]

  • 2. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 4. [The results of wet AMD treatment by intravitreal injections--preliminary report].
    Okruszko A, Borucka AI, Ulińska M, Szaflik J.
    Klin Oczna; 2007 Dec; 109(10-12):389-93. PubMed ID: 18488380
    [Abstract] [Full Text] [Related]

  • 5. Ranibizumab: Phase III clinical trial results.
    Rosenfeld PJ, Rich RM, Lalwani GA.
    Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
    [Abstract] [Full Text] [Related]

  • 6. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Sep; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S, Rosenfeld PJ.
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [Abstract] [Full Text] [Related]

  • 8. Role of vascular endothelial growth factor in ocular angiogenesis.
    Shams N, Ianchulev T.
    Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
    [Abstract] [Full Text] [Related]

  • 9. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [Abstract] [Full Text] [Related]

  • 10. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.
    Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM.
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [Abstract] [Full Text] [Related]

  • 15. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A.
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [Abstract] [Full Text] [Related]

  • 16. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [Abstract] [Full Text] [Related]

  • 17. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I, Zografos L, Ambresin A.
    Ophthalmologica; 2008 Feb; 222(5):321-3. PubMed ID: 18617755
    [Abstract] [Full Text] [Related]

  • 18. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [Abstract] [Full Text] [Related]

  • 19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 20. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
    Figurska M, Robaszkiewicz J, Wierzbowska J.
    Klin Oczna; 2010 Jul; 112(4-6):147-50. PubMed ID: 20825071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.